AUTHOR=Zheng Jingming , Luo Zhenhuan , Chiu Kin , Li Yimin , Yang Jing , Zhou Qinghua , So Kwok-Fai , Wan Qin-Li 

TITLE=Lycium barbarum glycopetide prolong lifespan and alleviate Parkinson’s disease in Caenorhabditis elegans

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=Volume 15 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1156265

DOI=10.3389/fnagi.2023.1156265

ISSN=1663-4365

ABSTRACT=Lycium barbarum glycopeptide (LbGp) is the main bioactive compound extracted from the traditional Chinese medicine L. barbarum berries and has been proven to have numerous health benefits, including antioxidative, anti-inflammatory, anticancer, and cytoprotective activities. However, the antiaging effect of LbGp remains unknown. In this study, using Caenorhabditis elegans (C. elehgans) as a model, we found that LbGp treatment prolonged the lifespan and health span of C. elegans. Mechanistically, we found that LbGp could activate the transcription factors DAF-16/FOXO, SKN-1/Nrf2, and HSF-1, as well as the nuclear receptor DAF-12, thereby upregulating longevity-related genes to achieve lifespan extension. In addition, we found that the lifespan extension induced by LbGp partially depends on mitochondrial function. Intriguingly, LbGp also ameliorated neurodegenerative diseases such as Parkinson’s disease in a DFA-16-, SKN-1- and HSF-1-dependent manner. Our work suggests that LbGp might be a viable candidate for the treatment and prevention of aging and age-related diseases.